New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first readout targets 2027. SPVN06, a novel gene-agnostic adeno-associated virus ...

In patients with COPD and atrial fibrillation or flutter, vitamin K antagonists carry a lower 1‑year risk for hospitalization ...

By slicing and dicing the data, the study confirms MITRA-FR as an outlier and emphasizes the need for careful patient selection.

Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal ...

SonicWall MPSS and Managed XDR, delivered by LOOPHOLD, unlock new growth opportunities for African MSPsIssued by Loophold Security DistributionJohannesburg, 10 Feb 2026 SonicWall MPSS supports ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Following Mesoblast's breakthrough FDA approval for its stem-cell therapy, activity in the sector has burgeoned and investors should stay tuned ... Read More The post Biocurious: Without a hint of ...

Global eClinical Solutions Market size was valued at USD 13.75 billion in 2024 and is projected to grow at a CAGR of 12.69% from 2025 to 2032, reaching nearly USD 35.76 billion by 2032.

Researchers at Huntress and Microsoft have shared findings from their analysis of a new SolarWinds Web Help Desk vulnerability.

BlueCat Networks, the leader in Intelligent NetOps, today announced BlueCat Horizon, a SaaS-based platform designed to modernize how enterprises and mid-market organizations operate, secure, and ...

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...

Q4 2025 Earnings Call February 10, 2026 8:00 AM ESTCompany ParticipantsAlexis Smith - Vice President & Head of ...